Published in J Thromb Haemost on October 01, 2013
Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation in vivo via an adenosine-dependent mechanism. FASEB J (2016) 1.38
Effects of P2Y12 receptor antagonists beyond platelet inhibition - comparison of ticagrelor with thienopyridines. Br J Pharmacol (2016) 0.81
G-protein-coupled receptors signaling pathways in new antiplatelet drug development. Arterioscler Thromb Vasc Biol (2015) 0.81
Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clin Pharmacokinet (2015) 0.80
P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use. Ther Adv Chronic Dis (2015) 0.80
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med (2015) 0.79
Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis. J Thromb Haemost (2014) 0.79
Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis. Vascul Pharmacol (2015) 0.78
Blood cells: an historical account of the roles of purinergic signalling. Purinergic Signal (2015) 0.78
Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. Arterioscler Thromb Vasc Biol (2017) 0.75
Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood (2016) 0.75
Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-Over Study in Healthy Subjects In Vivo. PLoS One (2015) 0.75
Microfludic platforms for the evaluation of anti-platelet agent efficacy under hyper-shear conditions associated with ventricular assist devices. Med Eng Phys (2017) 0.75
Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost (2006) 2.99
Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost (2005) 1.83
Amelioration of lipid-induced insulin resistance in rat skeletal muscle by overexpression of Pgc-1β involves reductions in long-chain acyl-CoA levels and oxidative stress. Diabetologia (2011) 1.59
Prevention of tumour cell dissemination in diagnostic needle procedures. Br J Cancer (2010) 1.57
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-). Phys Rev Lett (2012) 1.50
Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med (1997) 1.45
Determination of the X(3872) meson quantum numbers. Phys Rev Lett (2013) 1.42
Liver transplantation in severe von Willebrand disease. Lancet (1991) 1.40
Frequency of factor V Arg506 Gln in Italians. Thromb Haemost (1996) 1.39
Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost (2001) 1.34
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation (1994) 1.28
First observation of CP violation in the decays of B(s)0 mesons. Phys Rev Lett (2013) 1.21
Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost (2009) 1.21
Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost (1997) 1.17
Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem (1991) 1.15
DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood (1984) 1.10
Reply to: 'the discovery of a new class of synaptic transmitters in smooth muscle fifty years ago and amelioration of coronary artery thrombosis'. Acta Physiol (Oxf) (2013) 1.09
Multicenter study of homocysteine measurement--performance characteristics of different methods, influence of standards on interlaboratory agreement of results. Thromb Haemost (2001) 1.08
Cirrhosis associated with multiple transfusions in thalassaemia. Arch Dis Child (1984) 1.07
Effects of mutations in glycosylation sites and disulphide bonds on processing, CD4-binding and fusion activity of human immunodeficiency virus envelope glycoproteins. J Gen Virol (1991) 1.04
Mechanisms of platelet aggregation. Curr Opin Hematol (2001) 1.02
Increased fibrinopeptide A after prothrombin complex concentrates. Thromb Haemost (1980) 1.02
Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol (1995) 1.01
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab (2013) 0.99
Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment. Haemophilia (2006) 0.96
Measurement of form-factor-independent observables in the decay B0→K(*0)μ(+)μ(-). Phys Rev Lett (2013) 0.96
Production of a monoclonal antibody directed against the recombinant SEL1L protein. Int J Biol Markers (2002) 0.96
Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study. Diabetes Obes Metab (2012) 0.95
Observation of a resonance in B+ → K+ μ+ μ- decays at low recoil. Phys Rev Lett (2013) 0.95
Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet (1987) 0.95
Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol (1992) 0.95
The use of non-correlated log P and (log P) 2 values in quantitative structure activity relationships. Acta Pharm Suec (1980) 0.94
Isolation of a pancreas-specific gene located on human chromosome 14q31: expression analysis in human pancreatic ductal carcinomas. Genomics (1997) 0.94
High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb (1994) 0.93
[Project, natural lighting and comfort indoor]. Ann Ig (2008) 0.92
Rare bleeding disorders. Haemophilia (2008) 0.92
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J (2013) 0.91
Bile lipid composition and haemostatic variables in a case of high density lipoprotein deficiency (Tangier disease). Eur J Clin Invest (1984) 0.91
von Willebrand disease: laboratory aspects of diagnosis and treatment. Haemophilia (2004) 0.90
Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. J Thromb Haemost (2011) 0.89
Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements. Int J Clin Lab Res (1991) 0.89
Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis. Thromb Haemost (1986) 0.89
Effect of platelet count on platelet aggregation measured with impedance aggregometry (Multiplate™ analyzer) and with light transmission aggregometry. J Thromb Haemost (2013) 0.86
Effect of calcium ion concentration on the ability of fibrinogen and von Willebrand factor to support the ADP-induced aggregation of human platelets. Blood (1987) 0.86
Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost (2007) 0.86
High-D-dimer plasma levels predict poor outcome in esophageal variceal bleeding. Dig Liver Dis (2008) 0.86
Early presence of activated ('exhausted') platelets in malignant tumors (breast adenocarcinoma and malignant melanoma). Eur J Cancer Clin Oncol (1989) 0.86
Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol (1995) 0.85
Risk management of HBsAg or anti-HCV positive healthcare workers in hospital. Dig Liver Dis (2001) 0.84
[A hyperhomocysteinemia study in a population with a familial factor for acute myocardial infarct and sudden cardiac death at a young age]. Cardiologia (1999) 0.84
Changes of prothrombin fragment 1+2 (F 1+2) as a function of increasing intensity of oral anticoagulation--considerations on the suitability of F 1+2 to monitor oral anticoagulant treatment. Thromb Haemost (1998) 0.84
Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential. J Thromb Haemost (2008) 0.83
Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival. Thromb Res (1985) 0.83
Ontogenetic development and spatial distribution of the ileal apical sodium-dependent bile acid transporter and the ileal lipid-binding protein in apoE knockout and C57BL/6 mice. Scand J Gastroenterol (2002) 0.83
An automatic contour propagation method to follow parotid gland deformation during head-and-neck cancer tomotherapy. Phys Med Biol (2011) 0.83
Usefulness of a flow cytometric analysis of intraplatelet vasodilator-stimulated phosphoprotein phosphorylation for the detection of patients with genetic defects of the platelet P2Y(12) receptor for ADP. J Thromb Haemost (2010) 0.83
Platelet survival and thrombosis. Arteriosclerosis (1983) 0.83
First evidence for the decay B(s)(0)→μ+ μ-. Phys Rev Lett (2013) 0.83
The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Thromb Haemost (1999) 0.83
SEL1L, the human homolog of C. elegans sel-1: refined physical mapping, gene structure and identification of polymorphic markers. Hum Genet (2000) 0.82
Fibrinogen-independent aggregation and deaggregation of human platelets: studies in two afibrinogenemic patients. Blood (1987) 0.82
Cardiac relapses in myeloid leukemia: case report and review of the literature. Pediatr Hematol Oncol (1987) 0.82
Absence of hyperhomocysteinemia in ten patients with primary pulmonary hypertension. Thromb Res (1997) 0.82
Peripheral blood lymphocyte subpopulations in patients with viral warts. Acta Derm Venereol (1986) 0.81
Human platelet aggregation and release reaction induced by platelet activating factor (PAF-acether)--effects of acetylsalicylic acid and external ionized calcium. Thromb Haemost (1985) 0.81
Desmopressin and blood loss after cardiac surgery. Lancet (1993) 0.81
Topoisomerase II is nonfunctional in polyamine-depleted cells. J Cell Biochem (1999) 0.81
Measurement of the CP asymmetry in B(+)→K(+)μ(+)μ(-) decays. Phys Rev Lett (2013) 0.81
Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J Thromb Haemost (2014) 0.81
APOE-491 promoter polymorphism is a risk factor for late-onset Alzheimer's disease. Neurology (1999) 0.81
Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. J Thromb Haemost (2014) 0.81
Complete mutation scanning of the human SEL 1L gene: a candidate gene for type 1 diabetes. Acta Diabetol (2001) 0.80
Structural stability of Sclerotium rolfsii ATCC 201126 beta-glucan with fermentation time: a chemical, infrared spectroscopic and enzymatic approach. J Appl Microbiol (2008) 0.80
New approaches for measuring coagulation. Haemophilia (2006) 0.80
Measurement of the CP asymmetry in B(0)→K(*0)μ(+)μ(-) decays. Phys Rev Lett (2013) 0.80
Multiple dental extractions with a new prothrombin complex concentrate in two patients with factor VIII inhibitors. Thromb Res (1979) 0.80
Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res (2009) 0.79
Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood (1986) 0.79
Effect of prasugrel in patients with asthma: results of PRINA, a randomized, double-blind, placebo-controlled, cross-over study. J Thromb Haemost (2014) 0.79
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med (1996) 0.79
Olfactory function in painters exposed to organic solvents. Scand J Work Environ Health (1989) 0.79
Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer. Q J Nucl Med Mol Imaging (2005) 0.79
Patients with congenital abnormality of platelet aggregation induced by Ca(2+) ionophores may have a defect of the platelet P2Y(12) receptor for ADP. Br J Haematol (2001) 0.79
Airway repair with pedicled composite grafts--clinical experience. Otolaryngol Head Neck Surg (1987) 0.78
Primary polypeptide hormones and mucin-producing malignant carcinoid of the larynx. Ultrastruct Pathol (1983) 0.78
Homocysteine and cardiovascular diseases. Circulation (1999) 0.78
Identification of a novel polymorphism in the fibronectin type II domain of the SEL1L gene and possible relation to the persistent hyperinsulinemic hypoglycemia of infancy. Mutat Res (2004) 0.78
No evidence for SEL1L as a candidate gene for IDDM11-conferred susceptibility. Diabetes Metab Res Rev (2001) 0.78
Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency. Thromb Haemost (2014) 0.78
The in vitro production of thromboxane B2 by platelets of diabetic patients is normal at physiological concentrations of ionized calcium. Thromb Haemost (1993) 0.78
Is hyperhomocysteinemia a risk factor or a consequence of coronary heart disease? Arch Intern Med (2001) 0.78
Determination of f(s)/f(d) for 7 TeV pp collisions and measurement of the B0→D-K+ branching fraction. Phys Rev Lett (2011) 0.78
Observation of B(s)(0) → J/ψf(2)'(1525) in J/ψK+ K- final states. Phys Rev Lett (2012) 0.77
Felodipine analogs: structure-activity relationships. J Cardiovasc Pharmacol (1987) 0.77